This article is more than 5 years old. Information may no longer be current.
ImmunID begins enrollment in predictive treatment-response trial for melanoma
Click Here to Manage Email Alerts
ImmunID announced it has begun enrollment in its PREDICT-ID melanoma study to measure the predictive value of immune profiles to Yervoy.
The Grenoble, France-based immune molecular diagnostics company announced that the first two clinical centers in the study, in Lyon and Angers, have recruited five patients with metastatic melanoma, according to a press release. Six additional French centers are expected to join the study, as well.
The PREDICT-ID study will use ImmunID’s ImmunTraCkeR to evaluate immune competence profiles as a predictive biomarker of response to Yervoy (ipilimumab, Bristol-Myers Squibb) in metastatic melanoma, according to the release.
“Preliminary data on the utility of ImmunTraCkeR to predict response to ipilimumab in metastatic melanoma patients were generated in collaboration with the Memorial Sloan Kettering Cancer Center,” David Liens, MD, ImmunID’s chief medical officer, said in the release. “With PREDICT-ID, we want to validate these data in a larger patient population.”
The ImmuTraCkeR evaluates patient immune competence based on combinatorial T-cell diversity, according to the release.
Reference: www.immunid.com.